To this, we can add the recent myocardial infarction subgroup analysis from the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) study (evolocumab vs standard care).10, 21. The gene discussed is PCSK9; the disease is myocardial infarction.